Immunization with a chimera consisting of the B subunit of Shiga toxin type 2 and Brucella lumazine synthase confers total protection against Shiga toxins in mice

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2403-2411

  Mejias, María P ^a   Ghersi, Giselle ^b   Craig, Patricio O ^c   Panek, Cecilia A ^a   Bentancor, Leticia V ^a   Baschkier, Ariela ^d   Goldbaum, Fernando A ^b,c   Zylberman, Vanesa ^b,c   Palermo, Marina S ^a  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b Gral San Martín   (Argentina)

^c FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^d INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; BRUCELLA LUMAZINE SYNTHASE; DNA VACCINE; SHIGA TOXIN; SHIGA TOXIN 2 SUBUNIT B; SYNTHETASE; UNCLASSIFIED DRUG; VEROTOXIN 2;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CIRCULAR DICHROISM; CONTROLLED STUDY; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENTEROHEMORRHAGIC ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI INFECTION; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; LIGHT SCATTERING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; BRUCELLA; DISEASE MODELS, ANIMAL; ENTEROHEMORRHAGIC ESCHERICHIA COLI; FEMALE; HEMOLYTIC-UREMIC SYNDROME; MALE; MICE; MICE, INBRED BALB C; MULTIENZYME COMPLEXES; RECOMBINANT PROTEINS; SHIGA TOXIN 2; SHIGELLA VACCINES;

EID: 84883363423     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300999     Document Type: Article

References (59)

1. Kaper, J. B., J. P. Nataro, and H. L. Mobley. 2004. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2: 123-140.
2. Karmali, M. A. 1989. Infection by verocytotoxin-producing Escherichia coli. Clin. Microbiol. Rev. 2: 15-38.
3. Caprioli, A., S. Morabito, H. Brugère, and E. Oswald. 2005. Enterohaemorrhagic Escherichia coli: emerging issues on virulence and modes of transmission. Vet. Res. 36: 289-311.
4. Griffin, P. M., and R. V. Tauxe. 1991. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol. Rev. 13: 60-98.
5. López, E. L., V. Prado-Jiménez, M. O'Ryan-Gallardo, and M. M. Contrini. 2000. Shigella and Shiga toxin-producing Escherichia coli causing bloody diarrhea in Latin America. Infect. Dis. Clin. North Am. 14: 41-65, viii.
6. Rivas, M., E. Miliwebsky, I. Chinen, N. Deza, and G. A. Leotta. 2006. [The epidemiology of hemolytic uremic syndrome in Argentina. Diagnosis of the etiologic agent, reservoirs and routes of transmission]. Medicina (B. Aires) 66(Suppl. 3): 27-32.
7. Noël, J. M., and E. C. Boedeker. 1997. Enterohemorrhagic Escherichia coli: a family of emerging pathogens. Dig. Dis. 15: 67-91.
8. O'Brien, A. D., V. L. Tesh, A. Donohue-Rolfe, M. P. Jackson, S. Olsnes, K. Sandvig, A. A. Lindberg, and G. T. Keusch. 1992. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr. Top. Microbiol. Immunol. 180: 65-94.
9. Donohue-Rolfe, A., D. W. Acheson, and G. T. Keusch. 1991. Shiga toxin: purification, structure, and function. Rev. Infect. Dis. 13(Suppl. 4): S293-S297.
10. Lingwood, C. A. 1996. Role of verotoxin receptors in pathogenesis. Trends Microbiol. 4: 147-153.
11. Friedrich, A.W., M. Bielaszewska,W. L. Zhang, M. Pulz, T. Kuczius, A. Ammon, and H. Karch. 2002. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J. Infect. Dis. 185: 74-84.
12. Rüssmann, H., H. Schmidt, J. Heesemann, A. Caprioli, and H. Karch. 1994. Variants of Shiga-like toxin II constitute a major toxin component in Escherichia coli O157 strains from patients with haemolytic uraemic syndrome. J. Med. Microbiol. 40: 338-343.
13. Beddoe, T., A. W. Paton, J. Le Nours, J. Rossjohn, and J. C. Paton. 2010. Structure, biological functions and applications of the AB5 toxins. Trends Biochem. Sci. 35: 411-418.
14. Johannes, L., and W. Römer. 2010. Shiga toxins - from cell biology to biomedical applications. Nat. Rev. Microbiol. 8: 105-116.
15. Smith, M. J., L. D. Teel, H. M. Carvalho, A. R. Melton-Celsa, and A. D. O'Brien. 2006. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 24: 4122-4129.
16. Wen, S. X., L. D. Teel, N. A. Judge, and A. D. O'Brien. 2006. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 24: 1142-1148.
17. Tsuji, T., T. Shimizu, K. Sasaki, Y. Shimizu, K. Tsukamoto, H. Arimitsu, S. Ochi, S. Sugiyama, K. Taniguchi, P. Neri, and H. Mori. 2008. Protection of mice from Shiga toxin-2 toxemia by mucosal vaccine of Shiga toxin 2B-His with Escherichia coli enterotoxin. Vaccine 26: 469-476.
18. Bentancor, L. V., M. Bilen, R. J. Brando, M. V. Ramos, L. C. Ferreira, P. D. Ghiringhelli, and M. S. Palermo. 2009. A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model. Clin. Vaccine Immunol. 16: 712-718.
19. Marcato, P., G. Mulvey, R. J. Read, K. Vander Helm, P. N. Nation, and G. D. Armstrong. 2001. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J. Infect. Dis. 183: 435-443.
20. Bachmann, M. F., U. H. Rohrer, T. M. Kündig, K. Bürki, H. Hengartner, and R. M. Zinkernagel. 1993. The influence of antigen organization on B cell responsiveness. Science 262: 1448-1451.
21. Kitova, E. N., G. L. Mulvey, T. Dingle, I. Sinelnikov, S. Wee, T. P. Griener, G. D. Armstrong, and J. S. Klassen. 2009. Assembly and stability of the shiga toxins investigated by electrospray ionization mass spectrometry. Biochemistry 48: 5365-5374.
22. Velikovsky, C. A., F. A. Goldbaum, J. Cassataro, S. Estein, R. A. Bowden, L. Bruno, C. A. Fossati, and G. H. Giambartolomei. 2003. Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used. Infect. Immun. 71: 5750-5755.
23. Zylberman, V., P. O. Craig, S. Klinke, B. C. Braden, A. Cauerhff, and F. A. Goldbaum. 2004. High order quaternary arrangement confers increased structural stability to Brucella sp. lumazine synthase. J. Biol. Chem. 279: 8093-8101.
24. Bellido, D., P. O. Craig, M. V. Mozgovoj, D. D. Gonzalez, A. Wigdorovitz, F. A. Goldbaum, and M. J. Dus Santos. 2009. Brucella spp. lumazine synthase as a bovine rotavirus antigen delivery system. Vaccine 27: 136-145.
25. Cassataro, J., K. A. Pasquevich, S. M. Estein, D. A. Laplagne, C. A. Velikovsky, S. de la Barrera, R. Bowden, C. A. Fossati, G. H. Giambartolomei, and F. A. Goldbaum. 2007. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine 25: 4437-4446.
26. Laplagne, D. A., V. Zylberman, N. Ainciart, M. W. Steward, E. Sciutto, C. A. Fossati, and F. A. Goldbaum. 2004. Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides. Proteins 57: 820-828.
27. Creydt, V. P., M. F. Miyakawa, F. Martín, E. Zotta, C. Silberstein, and C. Ibarra. 2004. The Shiga toxin 2 B subunit inhibits net fluid absorption in human colon and elicits fluid accumulation in rat colon loops. Braz. J. Med. Biol. Res. 37: 799-808.
28. Capozzo, A. V., V. Pistone Creydt, G. Dran, G. Fernández, S. Gómez L. V. Bentancor, C. Rubel, C. Ibarra, M. Isturiz, and M. S. Palermo. 2003. Development of DNA vaccines against hemolytic-uremic syndrome in a murine model. Infect. Immun. 71: 3971-3978.
29. Fernández-Brando, R. J., L. V. Bentancor, M. P. Mejías, M. V. Ramos, A. Exeni, C. Exeni, Mdel. C. Laso, R. Exeni, M. A. Isturiz, and M. S. Palermo. 2011. Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods. PLoS ONE 6: e19136.
30. Ishikawa, S., K. Kawahara, Y. Kagami, Y. Isshiki, A. Kaneko, H. Matsui, N. Okada, and H. Danbara. 2003. Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1. Infect. Immun. 71: 3235-3239.
31. Bentancor, L. V., M. F. Bilen, M. P. Mejías, R. J. Fernández-Brando, C. A. Panek, M. V. Ramos, G. C. Fernández, M. Isturiz, P. D. Ghiringhelli, and M. S. Palermo. 2013. Functional capacity of Shiga-toxin promoter sequences in eukaryotic cells. PLoS ONE 8: e57128.
32. Ashkenazi, S., and T. G. Cleary. 1989. Rapid method to detect shiga toxin and shiga-like toxin I based on binding to globotriosyl ceramide (Gb3), their natural receptor. J. Clin. Microbiol. 27: 1145-1150.
33. Lasaro, M. A., C. Mathias-Santos, J. F. Rodrigues, and L. C. Ferreira. 2009. Functional and immunological characterization of a natural polymorphic variant of a heat-labile toxin (LT-I) produced by enterotoxigenic Escherichia coli (ETEC). FEMS Immunol. Med. Microbiol. 55: 93-99.
34. Brando, R. J., E. Miliwebsky, L. Bentancor, N. Deza, A. Baschkier, M. V. Ramos, G. C. Fernández, R. Meiss, M. Rivas, and M. S. Palermo. 2008. Renal damage and death in weaned mice after oral infection with Shiga toxin 2-producing Escherichia coli strains. Clin. Exp. Immunol. 153: 297-306.
35. Nagano, K., K. Taguchi, T. Hara, S. Yokoyama, K. Kawada, and H. Mori. 2003. Adhesion and colonization of enterohemorrhagic Escherichia coli O157:H7 in cecum of mice. Microbiol. Immunol. 47: 125-132.
36. Fernandez, M. I., A. Thuizat, T. Pedron, M. Neutra, A. Phalipon, and P. J. Sansonetti. 2003. A newborn mouse model for the study of intestinal pathogenesis of shigellosis. Cell. Microbiol. 5: 481-491.
37. Leotta, G. A., I. Chinen, S. Epszteyn, E. Miliwebsky, I. C. Melamed, M. Motter, M. Ferrer, E. Marey, and M. Rivas. 2005. [Validation of a multiplex PCR for detection of Shiga toxin-producing Escherichia coli]. Rev. Argent. Microbiol. 37: 1-10.
38. Ziebell, K. A., S. C. Read, R. P. Johnson, and C. L. Gyles. 2002. Evaluation of PCR and PCR-RFLP protocols for identifying Shiga toxins. Res. Microbiol. 153: 289-300.
39. Paton, A. W., and J. C. Paton. 1998. Detection and characterization of Shiga toxigenic Escherichia coli by using multiplex PCR assays for stx1, stx2, eaeA, enterohemorrhagic E. coli hlyA, rfbO111, and rfbO157. J. Clin. Microbiol. 36: 598-602.
40. Craig, P. O., V. Alzogaray, and F. A. Goldbaum. 2012. Polymeric Display of Proteins through High Affinity Leucine Zipper Peptide Adaptors. Biomacromolecules 13: 1112-1121.
41. Craig, P. O., P. M. Berguer, N. Ainciart, V. Zylberman, M. G. Thomas, L. J. Martinez Tosar, A. Bulloj, G. L. Boccaccio, and F. A. Goldbaum. 2005. Multiple display of a protein domain on a bacterial polymeric scaffold. Proteins 61: 1089-1100.
42. Lim, Y. S., B. Y. Kang, E. J. Kim, S. H. Kim, S. Y. Hwang, and T. S. Kim. 1998. Potentiation of antigen-specific, Th1 immune responses by multiple DNAvaccination with an ovalbumin/interferon-gamma hybrid construct. Immunology 94: 135-141.
43. Fernandez-Brando, R. J., E. Miliwebsky, M. P. Mejías, A. Baschkier, C. A. Panek, M. J. Abrey-Recalde, G. Cabrera, M. V. Ramos, M. Rivas, and M. S. Palermo. 2012. Shiga toxin-producing Escherichia coli O157 : H7 shows an increased pathogenicity in mice after the passage through the gastrointestinal tract of the same host. J. Med. Microbiol. 61: 852-859.
44. Cai, K., X. Gao, T. Li, Q. Wang, X. Hou, W. Tu, L. Xiao, M. Tian, Y. Liu, and H. Wang. 2011. Enhanced immunogenicity of a novel Stx2Am-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 29: 946-952.
45. Ling, H., A. Boodhoo, B. Hazes, M. D. Cummings, G. D. Armstrong, J. L. Brunton, and R. J. Read. 1998. Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry 37: 1777-1788.
46. Beutin, L., J. A. Hammerl, E. Strauch, J. Reetz, R. Dieckmann, Y. Kelner-Burgos, A. Martin, A. Miko, N. A. Strockbine, B. A. Lindstedt, et al. 2012. Spread of a distinct Stx2-encoding phage prototype among Escherichia coli O104:H4 strains from outbreaks in Germany, Norway, and Georgia. J. Virol. 86: 10444-10455.
47. Scheutz, F., E. M. Nielsen, J. Frimodt-Møller, N. Boisen, S. Morabito, R. Tozzoli, J. P. Nataro, and A. Caprioli. 2011. Characteristics of the enteroaggregative Shiga toxin/verotoxin-producing Escherichia coli O104:H4 strain causing the outbreak of haemolytic uraemic syndrome in Germany, May to June 2011. Euro Surveill. 16: 16.
48. Berguer, P. M., J. Mundiñano, I. Piazzon, and F. A. Goldbaum. 2006. A polymeric bacterial protein activates dendritic cells via TLR4. J. Immunol. 176: 2366-2372.
49. Ling, H., N. S. Pannu, A. Boodhoo, G. D. Armstrong, C. G. Clark, J. L. Brunton, and R. J. Read. 2000. A mutant Shiga-like toxin IIe bound to its receptor Gb(3): structure of a group II Shiga-like toxin with altered binding specificity. Structure 8: 253-264.
50. Fraser, M. E., M. Fujinaga, M. M. Cherney, A. R. Melton-Celsa, E. M. Twiddy, A. D. O'Brien, and M. N. James. 2004. Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J. Biol. Chem. 279: 27511-27517.
51. Coffman, R. L., A. Sher, and R. A. Seder. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
52. Demotz, S., C. Moulon, M. A. Roggero, N. Fasel, and S. Masina. 2001. Nativelike, long synthetic peptides as components of sub-unit vaccines: practical and theoretical considerations for their use in humans. Mol. Immunol. 38: 415-422.
53. Lima, K. M., S. A. dos Santos, J. M. Rodrigues, Jr., and C. L. Silva. 2004. Vaccine adjuvant: it makes the difference. Vaccine 22: 2374-2379.
54. Reed, S. G., S. Bertholet, R. N. Coler, and M. Friede. 2009. New horizons in adjuvants for vaccine development. Trends Immunol. 30: 23-32.
55. Robinson, C. M., J. F. Sinclair, M. J. Smith, and A. D. O'Brien. 2006. Shiga toxin of enterohemorrhagic Escherichia coli type O157:H7 promotes intestinal colonization. Proc. Natl. Acad. Sci. USA 103: 9667-9672.
56. Mohawk, K. L., A. R. Melton-Celsa, C. M. Robinson, and A. D. O'Brien. 2010. Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7. Vaccine 28: 4777-4785.
57. Hoey, D. E., C. Currie, R. W. Else, A. Nutikka, C. A. Lingwood, D. L. Gally, and D. G. Smith. 2002. Expression of receptors for verotoxin 1 from Escherichia coli O157 on bovine intestinal epithelium. J. Med. Microbiol. 51: 143-149.
58. Law, M., R. M. Cardoso, I. A. Wilson, and D. R. Burton. 2007. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J. Virol. 81: 4272-4285.
59. Davtyan, H., M. Mkrtichyan, N. Movsesyan, I. Petrushina, G. Mamikonyan, D. H. Cribbs, M. G. Agadjanyan, and A. Ghochikyan. 2010. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wildtype mice. Gene Ther. 17: 261-271.